
Comphya Closes Oversubscribed CHF 7.5 Million Series A Round

Share this article
Comphya SA, a Vaud-based clinical-stage MedTech company pioneering the first implantable neurostimulation therapy for erectile dysfunction (ED) unresponsive to medication, announced the closing of an oversubscribed Series A financing round. Including the conversion of existing convertible loans, the round brings Comphya’s total equity raised to CHF 7.5 million (~USD 8.4 million).
“We are thrilled to have the continued confidence of our investors, which enables us to accelerate our mission to bring a transformative solution to men living with erectile dysfunction following treatment for prostate cancer,” said Pim van Wesel, CEO of Comphya. “With our U.S. pilot study underway and preparations beginning for a pivotal clinical trial, we’re entering an important new chapter in our development.”
Proceeds from the Series A will be used to:
- Launch and execute a U.S. pilot study, with the first site activated at Johns Hopkins following FDA Investigational Device Exemption (IDE) approval announced in January 2025.
- Prepare for a pivotal U.S. clinical trial planned for 2026, including regulatory and operational groundwork.
- Expand Comphya’s ongoing clinical trial in Australia, where early data has shown strong safety and efficacy signals by recruiting additional patients.
The funding comes on the heels of highly encouraging clinical results from the company’s first-in-human study in Australia, where patients undergoing robotic-assisted prostatectomy were implanted with Comphya’s CaverSTIM™ system. Results presented at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas showed that a large majority of patients maintained good erectile function postoperatively without the need for adjunctive therapies. No infections or adverse events were reported. These early outcomes underscore the potential of CaverSTIM™ to fill a major gap in post-prostatectomy care, an area with no effective therapeutic options today.
The U.S. pilot study, now underway at Johns Hopkins, builds on the strong early data from Australia. Combined insights from both regions will guide the design of a pivotal clinical trial in 2026, which Comphya plans to fund through a forthcoming Series B round.
The Series A round also coincides with recent leadership changes at Comphya, including the appointment of industry veteran Pim van Wesel as CEO in May 2025 to guide the company through its next stage of clinical growth and strategic execution.
Comphya’s neurostimulator system is the first implantable therapy designed to restore natural erectile function by stimulating the cavernous nerves. Founded in 2017 as a spin-off from EPFL in Lausanne, the company aims to redefine the standard of care for patients who do not respond to conventional therapies.
➡️ Source: Press Release | 📸 Comphya